News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Amol Akhade: Real World Study of HR+/HER2- Breast Cancer from Tata Memorial India
Amol Akhade/hiranandanihospital.org
Jul 13, 2025, 14:22

Amol Akhade: Real World Study of HR+/HER2- Breast Cancer from Tata Memorial India

Amol Akhade, Consultant Medical Oncologist at Suyog Cancer Clinics, posted on X:

“Real world study from Tata Memorial India.

HR+/HER2– breast cancer (n=67)

Inclusion: Early/LABC patients on adjuvant hormone prescription

  • Sensitive = relapse-free ≥2 yrs (n=19)
  • Resistant = relapse <2 yrs or progression on AI/tamoxifen (n=48)

ctDNA (336-gene panel, ~11,500×) in 54 pts:

  • 25/35 (71.4%) resistant patients had actionable mutations
    -PIK3CA H1047X, AKT1 E17K, ESR1 E380Q, TP53, CDKN2A Q50*, ERBB2 D769Y, etc.
  • ESR1 mutations in 5/47 (10.6%) – all at relapse
  • 10/19 “sensitive” patients had drivers → 2 relapsed and died

ctDNA profiling in HR+/HER2– breast cancer reveals early resistance drivers and can predict relapse before clinical progression.”

Title: Genomic landscape of hormone therapy-resistant HR-positive, HER2-negative breast cancer

Journal: Breast Cancer Research and Treatment

Authors: Rohan Chaubal, Elizabeth Talker, Jaya Chitra , Rasika Kadam, Nilesh Gardi, Riddhi Ursekar, Anushree Kadam, Ankita Singh, Suhani Sale, Shwetali Pandey, Mrudula Madhav, Aishwarya Raja, Rushikesh Mukhare, Pallavi Parab, Nitin Shetty, Kunal Gala, Suyash Kulkarni, Khushboo A. Gandhi, Seema Gulia, Shalaka Joshi, Tanuja Shet, Sudeep Gupta

Read the full article.

Amol Akhade

More posts featuring Amol Akhade on OncoDaily.

Aishwarya Raja Amol Akhade Ankita Singh Anushree Kadam Breast Cancer Breast Cancer Research and Treatment cancer ctDNA profiling Elizabeth Talker ESR1 mutation Jaya Chitra Khushboo A. Gandhi Kunal Gala Mrudula Madhav Nilesh Gardi Nitin Shetty OncoDaily Oncology Pallavi Parab Rasika Kadam Riddhi Ursekar Rohan Chaubal Rushikesh Mukhare Seema Gulia Shalaka Joshi Shwetali Pandey Sudeep Gupta Suhani Sale Suyash Kulkarni Suyog Cancer Clinics tamoxifen Tanuja Shet Tata Memorial India
Special Coverage
Insight
Jul 13, 2025, 14:22
Amol Akhade: Real World Study of HR+/HER2- Breast Cancer from Tata Memorial India
Insight
Jul 13, 2025, 13:57
Mario Balsa: A PI3K Path Worth Walking - If You Can Manage the Steps
Blog
Jul 13, 2025, 13:54
Patrick Hwu: Can Exercise Really Help Fight Cancer?
Science
Jul 13, 2025, 13:50
Myeloma Paper of the Day, July 13th, Suggested by Robert Orlowski
Blog
Jul 13, 2025, 13:47
Paolo Ascierto: Naples and Italian Oncology Need Role Models Like You
Blog
Jul 13, 2025, 13:40
Gregg Margolis: Three Things About Health Policy This Week
Blog
Jul 13, 2025, 13:34
Florian Lordick: ESMO Preceptorship on Oesophageal and Gastric Cancer
Blog
Jul 13, 2025, 13:33
Vivek Subbiah: Essential Tools Toward More Globally Inclusive and Data-Driven Drug Development
Drugs
Jul 13, 2025, 13:27
Shaheenah Dawood: Phase 2 RAMP201 Trial Leading to FDA Accelerated Approval of Avumetinib and Defactinib
Opinion
Jul 13, 2025, 13:25
Agrima Mian: ASH Committee on Communications Summer 2025 Meeting
Blog
Jul 13, 2025, 13:20
Abstract Deadline Extended for the IASLC 2025 Asia Conference on Lung Cancer
Blog
Jul 13, 2025, 13:18
Wafaa M Rashed: The 9th Cohort of the Policy Advocacy in Genetics and Genomics Course